144 related articles for article (PubMed ID: 14575377)
21. Washout rates of Tc-99m tetrofosmin in asymmetric septal hypertrophy.
Büyükdereli G; Kanadasi M; Kibar M
Ann Nucl Med; 2005 Feb; 19(1):29-33. PubMed ID: 15770970
[TBL] [Abstract][Full Text] [Related]
22. Predicting the response to cardiac resynchronization therapy using 99mTc-tetrofosmin myocardial scintigraphy in patients with drug-refractory heart failure: additional value of the washout of 99mTc-tetrofosmin.
Shigeru M; Fujiwara S; Takamine S; Yoshida A; Kawai H; Shiotani H; Hirata K
Nucl Med Commun; 2014 Sep; 35(9):939-46. PubMed ID: 24977350
[TBL] [Abstract][Full Text] [Related]
23. P-glycoprotein versus MRP1 on transport kinetics of cationic lipophilic substrates: a comparative study using [99mTc]sestamibi and [99mTc]tetrofosmin.
Gomes CM; Abrunhosa AJ; Pauwels EK; Botelho MF
Cancer Biother Radiopharm; 2009 Apr; 24(2):215-27. PubMed ID: 19409044
[TBL] [Abstract][Full Text] [Related]
24. A single (99m)Tc-MIBI study to predict response to neoadjuvant treatment in sarcoma patiens.
Sohaib M; Wiqar MA; Ali MK; Hussain F; Umer-i-Farooq
Hell J Nucl Med; 2011; 14(2):140-5. PubMed ID: 21761016
[TBL] [Abstract][Full Text] [Related]
25. The usefulness of 99mTc-tetrofosmin SPECT in the detection of lung metastases from extrapulmonary primary tumors.
Spanu A; Solinas ME; Farris A; Arru A; Chessa F; Madeddu G; Falchi A; Madeddu G
Radiol Med; 2004; 107(1-2):113-27. PubMed ID: 15031703
[TBL] [Abstract][Full Text] [Related]
26. Myocardial technetium-99m-tetrofosmin and technetium-99m-sestamibi kinetics in normal subjects and patients with coronary artery disease.
Münch G; Neverve J; Matsunari I; Schröter G; Schwaiger M
J Nucl Med; 1997 Mar; 38(3):428-32. PubMed ID: 9074532
[TBL] [Abstract][Full Text] [Related]
27. Size and P-glycoprotein expression limit 99mTc-tetrofosmin uptake in parathyroid adenomas.
Huang WT
Nucl Med Commun; 2002 Oct; 23(10):1001-4. PubMed ID: 12352599
[TBL] [Abstract][Full Text] [Related]
28. Technetium-99m-tetrofosmin scintigraphy in patients with metastatic soft tissue sarcoma.
Karanikas G; Köstler WJ; Becherer A; Wiesner K; Dudczak R; Krainer M; Kletter K
Oncol Rep; 2002; 9(5):1009-13. PubMed ID: 12168065
[TBL] [Abstract][Full Text] [Related]
29. Predicting chemotherapy response and comparing with P-glycoprotein expression using technetium-99m tetrofosmin scan in untreated malignant lymphomas.
Shiau YC; Tsai SC; Wang JJ; Ho YJ; Ho ST; Kao CH
Cancer Lett; 2001 Sep; 170(2):139-46. PubMed ID: 11463491
[TBL] [Abstract][Full Text] [Related]
30. To predict chemotherapy response using technetium-99m tetrofosmin and compare with p-glycoprotein and multidrug resistance related protein-1 expression in patients with untreated small cell lung cancer.
Shiau YC; Tsai SC; Wang JJ; Ho YJ; Ho ST; Kao CH
Cancer Lett; 2001 Aug; 169(2):181-8. PubMed ID: 11431107
[TBL] [Abstract][Full Text] [Related]
31. Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma.
Lind P; Gallowitsch HJ; Langsteger W; Kresnik E; Mikosch P; Gomez I
J Nucl Med; 1997 Mar; 38(3):348-52. PubMed ID: 9074515
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of Tc-99m-MIBI performed during middle course of preoperative chemotherapy in patients with malignant bone and soft-tissue tumors.
Wakabayashi H; Taki J; Inaki A; Sumiya H; Zen Y; Tsuchiya H; Kinuya S
Clin Nucl Med; 2012 Jan; 37(1):1-8. PubMed ID: 22157020
[TBL] [Abstract][Full Text] [Related]
33. Evaluating benign and malignant bone and soft-tissue lesions with technetium-99m-MIBI scintigraphy.
Taki J; Sumiya H; Tsuchiya H; Tomita K; Nonomura A; Tonami N
J Nucl Med; 1997 Apr; 38(4):501-6. PubMed ID: 9098190
[TBL] [Abstract][Full Text] [Related]
34. Clinical application of Tc-99m tetrofosmin scintigraphy in patients with cold thyroid nodules. Comparison with color Doppler sonography.
Erdem S; Baŝhekim C; Kizilkaya E; Ince M; Karsli F
Clin Nucl Med; 1997 Feb; 22(2):76-9. PubMed ID: 9031763
[TBL] [Abstract][Full Text] [Related]
35. Comparison of microsphere-equivalent blood flow (15O-water PET) and relative perfusion (99mTc-tetrofosmin SPECT) in myocardium showing metabolism-perfusion mismatch.
Schaefer WM; Nowak B; Kaiser HJ; Koch KC; Block S; vom Dahl J; Buell U
J Nucl Med; 2003 Jan; 44(1):33-9. PubMed ID: 12515874
[TBL] [Abstract][Full Text] [Related]
36. Technetium-99m-hexakis-2-methoxyisobutylisonitrile scintigraphy and multidrug resistance-related protein expression in human primary lung cancer.
Duan XY; Wang JS; Liu M; Guo YM
Ann Nucl Med; 2008 Jan; 22(1):49-55. PubMed ID: 18250987
[TBL] [Abstract][Full Text] [Related]
37. Correlation of 99mTc-sestamibi uptake with blood-pool and osseous phase 99mTc-MDP uptake in malignant bone and soft-tissue tumours.
Ozcan Z; Burak Z; Erinç R; Dirlik A; Başdemir G; Sabah D; Ozkiliç H
Nucl Med Commun; 2001 Jun; 22(6):679-83. PubMed ID: 11403180
[TBL] [Abstract][Full Text] [Related]
38. Enhanced washout of 99mTc-tetrofosmin in hypertrophic cardiomyopathy: quantitative comparisons with regional 123I-BMIPP uptake and wall thickness determined by MRI.
Thet-Thet-Lwin ; Takeda T; Wu J; Fumikura Y; Iida K; Kawano S; Yamaguchi I; Itai Y
Eur J Nucl Med Mol Imaging; 2003 Jul; 30(7):966-73. PubMed ID: 12756503
[TBL] [Abstract][Full Text] [Related]
39. Using technetium-99m tetrofosmin chest imaging to predict taxol-based chemotherapy response in non-small cell lung cancer but not related to lung resistance protein expression.
Shih CM; Shiau YC; Wang JJ; Ho ST; Kao A
Lung; 2003; 181(2):103-11. PubMed ID: 12953149
[TBL] [Abstract][Full Text] [Related]
40. Thallium-201 scintigraphy in bone and soft-tissue tumors: a comparison of dynamic, early and delayed scans.
Sugawara Y; Kikuchi T; Kajihara M; Semba T; Ochi T; Fujii T; Mochizuki T; Sakayama K; Nakata S
Ann Nucl Med; 2005 Sep; 19(6):461-8. PubMed ID: 16248382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
